Pyxis Oncology, Inc. (PYXS)

Name: Pyxis Oncology, Inc. (PYXS) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001782223 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, Pyxis Oncology, Inc. reported revenue of $13.86M. Revenue fell 14.2% from the prior annual period.

Key ratios (year ended 2025-12-31)

82.8%

Gross margin (computed)

-609.2%

Operating margin

-574.5%

Net margin

-149.1%

Return on year-end equity

-14.2%

Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4/A (ownership change) · 2026-10-09

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Revenue	n/a	$13.86M	$16.15M	n/a	n/a	n/a	n/a
Cost of Revenue	n/a	$2.39M	$475.0K	n/a	n/a	n/a	n/a
Gross Profit (computed)	n/a	$11.47M	n/a	n/a	n/a	n/a	n/a
R&D Expense	$75.56M	$73.70M	$58.75M	$49.59M	$86.13M	$51.05M	$9.05M
Operating Income	-$92.11M	-$84.42M	-$89.46M	-$82.20M	-$123.48M	-$69.72M	-$12.89M
Depreciation & Amortization	$4.18M	$4.51M	$2.98M	$1.93M	$709.0K	$647.0K	$469.0K
EBITDA	-$87.92M	-$79.91M	-$86.48M	-$80.27M	-$122.77M	-$69.07M	-$12.43M
Net Income	-$88.73M	-$79.62M	-$77.33M	-$73.79M	-$120.72M	-$75.97M	-$12.83M
EPS (Diluted)	n/a	-$1.28	-$1.32	-$1.85	-$3.65	-$8.95	n/a
Total Assets	$54.92M	$91.52M	$157.18M	$173.73M	$211.38M	$280.02M	$10.15M
Total Liabilities	$43.48M	$38.11M	$36.43M	$48.02M	$50.55M	$18.71M	$3.85M
Shareholders' Equity	$11.44M	$53.41M	$120.75M	$125.70M	$160.82M	$261.31M	-$15.64M
Cash & Equivalents	$18.86M	$15.42M	$19.47M	$9.66M	$179.29M	$274.74M	$8.08M
Operating Cash Flow	-$67.91M	-$63.50M	-$57.67M	-$70.71M	-$89.33M	-$35.33M	-$10.08M
Capital Expenditures	n/a	$9.0K	$237.0K	$6.73M	$6.40M	$540.0K	$1.48M
Free Cash Flow	n/a	-$63.51M	-$57.91M	-$77.44M	-$95.73M	-$35.87M	-$11.57M
Shares Outstanding	63.43M	62.69M	59.97M	44.75M	34.96M	32.22M	1.29M
Weighted Average Diluted Shares	n/a	62.14M	58.45M	39.90M	33.03M	8.49M	n/a
EPS (Basic)	n/a	-$1.28	-$1.32	-$1.85	-$3.65	-$8.95	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView